For most of the 20th century, the Food and Drug Administration (FDA) made progress toward ensuring patients could have confidence that their medicines were both safe and effective. But there is often tension between speedy access and certainty about the benefit of new drugs.
Beginning with the HIV patient advocacy movement, the FDA has increasingly emphasized flexibility, prioritizing access for patients facing serious diseases with no time to wait. This lecture will discuss the current challenges confronting the FDA as it seeks to address the needs of current and future patients.
Speaker:
Holly Fernandez Lynch
Associate Professor of Medical Ethics and Law at the University of Pennsylvania
The Joseph Priestley Society (JPS) promotes a deeper understanding of science, technology, and industry, with an emphasis on innovation and entrepreneurship. Speakers are leaders from a wide variety of large and small chemical companies and the financial, consulting, and academic communities.
To learn more about JPS events, visit www.sciencehis...
Негізгі бет Drug Regulation When Patients Can’t Wait | JPS
Пікірлер